A recent study found that Oncotype DX results changed the oncologist’s choice of treatment in about one third of cases. In breast cancer patients, the most common change in treatment involved a shift away from chemotherapy and hormone therapy, to hormone therapy alone. When used in conjunction with consensus guidelines and risk assessments, Oncotype DX and other gene profiling assays can help to determine appropriate treatment options, as well as overall survival, recurrence probability, and responsiveness to chemotherapy.
While flu seasons are unpredictable, the Centers for Disease Control and Prevention continues to recommend annual vaccination as the best tool for preventing influenza, as well as timely use of antiviral medications to treat influenza in select patients. In some cases, rapid diagnostic testing may be useful in selecting appropriate treatments. While antiviral drugs can help reduce the duration and severity of flu symptoms, the decision to use them must be based on individual evaluations of risk and benefit.